Latest Headlines
-
Andelyn Biosciences Announces Partnership With Jaguar Gene Therapy To Provide Late-Stage PPQ Manufacturing
12/8/2025
Andelyn Biosciences, a leading and patient-focused cell and gene therapy Contract Development and Manufacturing Organization (CDMO), has partnered with Jaguar Gene Therapy to perform late-stage Process Performance Qualification (PPQ) manufacturing of JAG201, an investigational gene therapy targeting SHANK3 haploinsufficiency which is clinically diagnosed as Phelan-McDermid syndrome (PMS), a leading monogenic cause of autism spectrum disorder (ASD).
-
Solid Biosciences Announces Licensing Agreement With Andelyn Biosciences For The Use Of Proprietary Next-Generation Capsid AAV-SLB101
11/17/2025
Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced a non-exclusive worldwide license and collaboration agreement with Andelyn Biosciences (Andelyn), a pioneering and patient-focused cell and gene therapy Contract Development and Manufacturing Organization (CDMO), for the use of Solid’s proprietary, next-generation capsid, AAV-SLB101.
-
AES Cleanroom Technology Establishes New Office In Research Triangle Park To Support Regional Drug Manufacturing Growth
11/11/2025
AES Cleanroom Technology, an award-winning leader in modular cleanroom design and construction, has opened a new regional office in Research Triangle Park (RTP), reinforcing its commitment to serving the Southeast’s fast-growing life sciences, biotechnology, and advanced manufacturing sectors.
-
Vector BioMed Expands LENTIVERSE™, Rebrands to Advance CGT
11/6/2025
Vector BioMed expands LENTIVERSE™ with two solutions, VectorCraft and LaunchSuite, to accelerate global gene therapy access through transparent economics, streamlined manufacturing, and a bold new brand.
-
Avance Clinical Showcases Early Phase Expertise And The Australian Advantage For EU Biotechs At BIO-Europe Vienna
11/5/2025
Avance Clinical, the largest premium full-service Australian headquartered CRO with more than 30 years of early phase expertise, is highlighting its Early Phase Center of Excellence for Biotechs and the well-established Australian Advantage to European biotechs ahead of BIO-Europe in Vienna, November 3-5, 2025.
-
Meet Avance Clinical At SCOPE Summit 2026 In Orlando, Florida
11/5/2025
Avance Clinical is excited to announce our participation in SCOPE Summit 2026, one of the most influential gatherings in clinical operations, where leading innovators in biotech, pharma, CROs, and technology come together to share strategies shaping the future of global drug development.
-
Avance Clinical Launches Renal And Cardiometabolic Center Of Excellence To Optimize Patient Recruitment To Elevate Study Success
10/30/2025
Avance Clinical, a partner for biotechs providing global contract research organization services, has announced the launch of the Renal & Cardiometabolic Center of Excellence.
-
Tema Sinergie Acquires Majority Stake In Aseptic Filling OEM 6Bio
10/29/2025
TEMA Sinergie S.p.A., a global leader in isolation systems for the Radiopharma and Biotech Pharma industries, today announced the acquisition of a majority stake in 6Bio, a Spanish company specialized in high-performance aseptic filling technology.
-
LOTTE BIOLOGICS And SK pharmteco Sign Strategic Partnership To Strengthen Global ADC CDMO Capabilities
10/29/2025
Through this collaboration, the two companies will jointly investigate providing integrated, one-stop CDMO services to global clients, offering differentiated ADC solutions that span from development to commercial manufacturing.
-
Avance Clinical Unveils Dedicated CNS Center Of Excellence For Expert Clinical Trial Services In Neuroscience
10/28/2025
Avance Clinical, the award-winning Australian-led, global CRO built exclusively to service the clinical research needs of biotech companies, today announced the launch of its Center of Excellence dedicated to central nervous system (CNS) disorders.